Indegene Limited reported FY26 revenue of ₹3,510.5 crore, a 23.6% increase. While PAT saw a marginal 1.4% dip to ₹401.1 crore, the company recommended a final dividend of ₹2.25 per share. Strategic acquisitions aimed at expanding its European footprint and AI capabilities are underway.

Indegene Limited FY2025-26 Results

Revenue from operations reached ₹3,510.5 crore, a 23.6% increase year-on-year. Consolidated EBITDA stood at ₹624.7 crore, up 11.1%. Profit After Tax (PAT) was ₹401.1 crore, a slight decrease of 1.4% from ₹406.7 crore in the previous fiscal.

Reader Takeaway: Strong revenue growth offset by margin pressure and recent acquisitions.

What just happened

Indegene Limited announced its financial results for the fiscal year ending March 31, 2026. The company reported consolidated revenue from operations of ₹3,510.5 crore, marking a significant 23.6% growth compared to the previous year's ₹2,839.3 crore. EBITDA saw a rise of 11.1% to ₹624.7 crore. However, consolidated PAT experienced a marginal decline of 1.4%, settling at ₹401.1 crore, down from ₹406.7 crore in FY 2024-25. Basic Earnings Per Share (EPS) also decreased by 2.5% to ₹16.72 from ₹17.15.

The company's Board has recommended a final dividend of ₹2.25 per equity share for the financial year. Additionally, Indegene completed strategic acquisitions during the fiscal year, including BioPharm in October 2025, and Warn & Co and Cake Kommunikations in January 2026. These moves are aimed at expanding its presence in European markets and enhancing its AI-driven commercialization services.

Ms. Jill Mary De Simone was appointed as an Independent Director, effective January 22, 2026, for a three-year term.

Why this matters

The results highlight Indegene's ability to grow its top-line significantly, surpassing ₹3,500 crore in annual revenue. This demonstrates market traction and successful business expansion. The recommended dividend signals a commitment to shareholder returns. However, the decline in PAT and EPS, coupled with a contraction in net profit margin to 11.4% from 14.3%, indicates pressure on profitability. Investors will be keen to understand how the recent acquisitions and investments will impact future margins and earnings.

The backstory

Indegene has been focusing on expanding its global footprint and capabilities in the life sciences sector. The company operates in a competitive landscape where innovation, particularly in AI and digital solutions, is crucial. Its strategy involves both organic growth and inorganic expansion through acquisitions to bolster its service offerings and market reach.

What changes now

With the new financial year commencing, investors will look for Indegene to leverage its expanded capabilities from recent acquisitions to drive not only revenue but also profitability. The integration of BioPharm, Warn & Co, and Cake Kommunikations will be a key focus. The appointment of a new independent director could bring fresh perspectives to board-level strategy and governance.

Risks to watch

The primary concern for investors is the sustained pressure on profit margins. While revenue grew robustly, the dip in PAT and the decline in net profit margin suggest that the cost of growth, potentially including integration costs from acquisitions, is impacting the bottom line. Monitoring the company's ability to improve operational efficiencies and price its services effectively will be crucial.

Peer comparison

While specific peer comparison data for this period is not provided in the filing, Indegene operates in the specialized segment of life sciences commercialization and marketing solutions. Key competitors in this space focus on digital transformation, data analytics, and regulatory support for pharmaceutical and biotech companies. Companies in this sector often face challenges balancing aggressive growth strategies with maintaining healthy profit margins.

Context metrics (time-bound)

• FY 2025-26 Revenue: ₹3,510.5 crore
• FY 2025-26 EBITDA: ₹624.7 crore
• FY 2025-26 PAT: ₹401.1 crore
• Revenue Growth (YoY): +23.6%
• PAT Change (YoY): -1.4%
• Net Profit Margin (FY26): 11.4% (down from 14.3% in FY25)
• Final Dividend: ₹2.25 per share
• Acquisitions: BioPharm (Oct 2025), Warn & Co, Cake Kommunikations (Jan 2026)
• New Director: Ms. Jill Mary De Simone (Appointed Jan 22, 2026)

What to track next

Investors should closely monitor Indegene's performance in the upcoming quarters, focusing on:

• Revenue growth trajectory and its quality.
• Trends in EBITDA and PAT margins.
• Successful integration and performance of acquired entities.
• The company's ability to translate revenue growth into enhanced profitability.
• Updates on AI-driven service offerings and market adoption.